Science Journal of Public Health

Special Issue

Obstructive Sleep Apnea: A Systemic Disease

  • Submission Deadline: Feb. 28, 2016
  • Status: Submission Closed
  • Lead Guest Editor: Aliae AR Mohamed-Hussein
About This Special Issue
Obstructive sleep apnea syndrome (OSAS) is a highly prevalent sleep disorder, characterized by repeated disruptions of breathing during sleep. This disease has many potential consequences including excessive daytime sleepiness, neurocognitive deterioration, endocrinologic and metabolic effects, and decreased quality of life. Metabolic syndrome is another highly prevalence emerging public health problem that represents a constellation of cardiovascular risk factors. Each single component of the cluster increases the cardiovascular risk, but the combination of factors is much more significant. It has been suggested that the presence of OSAS may increase the risk of developing some metabolic syndrome features. Moreover, OSAS patients are at an increased risk for vascular events, which represent the greatest morbidity and mortality of all associated complications.

Although the etiology of OSAS is uncertain, intense local and systemic inflammation is present. A variety of phenomena are implicated in this disease such as modifications in the autonomic nervous system, hypoxemia–reoxygenation cycles, inflammation, and coagulation–fibrinolysis imbalance. OSAS patients also present increased levels of certain biomarkers linked to endocrine-metabolic and cardiovascular alterations among other systemic consequences.

The Aim of this Special issue is to clarify that OSAS is more than a local abnormality, and it should be considered a systemic disease.
Lead Guest Editor
  • Aliae AR Mohamed-Hussein

    Chest Department, Assiut University Hospitals, Assiut, Egypt

Guest Editors
  • Jafar Al-Sharab

    Northwestern State University, Las Vegas, United States

  • Obair Siddiqui

    LG Electronics Inc., Detroit, United States

  • Klaus Dulhoff

    Pulmonology Department, Medical University of Lubeck, Lubeck, Germany

  • Tenor Henning Koth

    Pulmonology Department, Medical University of Lubeck, Lubeck, Germany

  • Andreas Rembert Koczulla

    Pulmonology Department, Marburg University, Marburg, Germany

  • Roland Buhl

    Pulmonary Department, Mainz University Hospital, Mainz, Germany

  • Hossam Gendi

    Essex Cardiac Center, Princess Alexandra Hospital, London, United Kingdom

  • John Moxham

    Physiology Department, Kings College London, London, United Kingdom

  • Micheal Polkey

    Physiology Department, Imperial College London, London, United Kingdom

  • Yoshino Ichiro

    Pulmonology Department, Chiba University, Chiba, Japan

  • Mohammed Obeidat

    Jordan University of Science and Technology, Amman, Jordan

  • Sherifa Hamed

    Department of Neurology and Psychiatry, Assiut University Hospital, Assiut, Egypt

  • Ayman Khairy

    Cardiology Department, Assiut University Hospitals, Assiut, Egypt

Published Articles
  • Sleep Related Conditions with Myasthenia Gravis: Evidence, Causes and Implications

    Sherifa Ahmed Hamed

    Issue: Volume 4, Issue 2-1, April 2016
    Pages: 6-16
    Received: Aug. 15, 2015
    Accepted: Aug. 17, 2015
    Published: Sep. 08, 2015
    DOI: 10.11648/j.sjph.s.2016040201.12
    Abstract: Myasthenia gravis (MG) is an autoimmune disease caused mainly by antibodies against skeletal muscle nicotinic acetylcholine receptors (nAChRs) at the postsynaptic membrane resulting in depletion of acetylcholine at the neuromuscular junction (NMJ). Muscle fatigue is the cardinal symptom of MG. Respiratory muscle weakness and breathing problems are ... Show More
  • Obstructive Sleep Apnoea: Another Burden on Cirrhotic Liver

    Aliae AR Mohamed-Hussein , Mohamed-Eltaher AA Ibrahim

    Issue: Volume 4, Issue 2-1, April 2016
    Pages: 1-5
    Received: Jul. 04, 2015
    Accepted: Jul. 06, 2015
    Published: Sep. 08, 2015
    DOI: 10.11648/j.sjph.s.2016040201.11
    Abstract: Obstructive sleep apnea syndrome (OSAS) may cause aggressive deterioration in the course of liver cirrhosis and may have an impact on the development of hepatic cell failure in patients with concomitant diseases. Patients and Methods: 34 patients with OSAS and compensated cirrhosis as well as 30 compensated cirrhotic patients were followed for 1 ye... Show More